Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia

被引:89
作者
Auerbach, Michael [1 ,2 ]
Pappadakis, Jennifer A. [3 ]
Bahrain, Huzefa [2 ]
Auerbach, Sarah A. [2 ]
Ballard, Harold [4 ]
Dahl, Naomi V. [3 ]
机构
[1] Georgetown Univ, Sch Med, Washington, DC 20057 USA
[2] Auerbach Hematol Oncol, Baltimore, MD USA
[3] Watson Labs Inc, Med Affairs, Parsippany, NJ USA
[4] NYU, Sch Med, Dept Med, New York, NY USA
关键词
INTRAVENOUS IRON; SERUM FERRITIN; ORAL IRON; INFUSION; THERAPY;
D O I
10.1002/ajh.22153
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Oral iron is a standard treatment of iron deficient anemia despite high rates of intolerance and nonadherence and may not replenish iron stores rapidly enough to meet ongoing losses [1]. Intravenous (IV) iron has advantages but remains underutilized. Whereas most formulations of IV iron require multiple doses for replacement, low molecular weight iron dextran (LMW ID) may be administered as a total dose infusion, typically over a 4- to 6-hr period [2,3]. A 4-hr infusion for doses up to 4 g was standard in our practice until 2 years ago. However, clinical studies suggest that 1 g of IV iron is an adequate dose for many patients [3-5], and it became apparent that we were frequently infusing doses of at least 1 g in 1 hr without evidence of significant adverse events [3]. Now, our clinical practice routinely infuses 1 g of LMW ID in 250 mL normal saline over 1 hr without premedication as our standard practice. We summarize our experience with the safety and efficacy of this method of administering IV iron in unselected patients with iron deficiency.
引用
收藏
页码:860 / 862
页数:3
相关论文
共 21 条
[1]
Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy [J].
AlMomen, AK ;
AlMeshari, A ;
AlNuaim, L ;
Saddique, A ;
Abotalib, Z ;
Khashogji, T ;
Abbas, M .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1996, 69 (02) :121-124
[2]
[Anonymous], 2008, NEW DRUG APPL NDA 22
[3]
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial [J].
Auerbach, M ;
Ballard, H ;
Trout, JR ;
McIlwain, M ;
Ackerman, A ;
Bahrain, H ;
Balan, S ;
Barker, L ;
Rana, J .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1301-1307
[4]
A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients [J].
Auerbach, M ;
Winchester, J ;
Wahab, A ;
Richards, K ;
McGinley, M ;
Hall, F ;
Anderson, J ;
Briefel, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (01) :81-86
[5]
AUERBACH M, 1988, J LAB CLIN MED, V111, P566
[6]
Clinical update: intravenous iron for anaemia [J].
Auerbach, Michael ;
Ballard, Harold ;
Glaspy, John .
LANCET, 2007, 369 (9572) :1502-1504
[7]
Ayub R, 2008, JCPSP-J COLL PHYSICI, V18, P424, DOI 07.2008/JCPSP.424427
[8]
Bailie GR, 2010, ARZNEIMITTELFORSCH, V60, P386, DOI 10.1055/s-0031-1296303
[9]
Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation [J].
Barton, JC ;
Barton, EH ;
Bertoli, LF ;
Gothard, CH ;
Sherrer, JS .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (01) :27-32
[10]
Anemia during pregnancy and treatment with intravenous iron: review of the literature [J].
Bashiri, A ;
Burstein, E ;
Sheiner, E ;
Mazor, M .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2003, 110 (01) :2-7